mTOR 억제제 시장 평가 : 유형, 용도, 최종사용자, 지역별 기회 및 예측(2017-2031년)

Global mTOR inhibitors market is projected to witness a CAGR of 5.1% during the forecast period 2024-2031, growing from USD 5.03 billion in 2023 to USD 7.49 billion in 2031. Due to the growing need for effective therapies for cancer, transplant procedures, and autoimmune illnesses, the market has experienced significant expansion and innovation over the historic period.

mTOR (mammalian target of rapamycin) inhibitors are essential for treating cancer, and suppressing the immune system, and are used to treat other medical conditions as well. The increasing incidence of cancer globally is one of the main factors driving the growth of the global market for mTOR inhibitors. mTOR inhibitors, including everolimus and temsiroIimus, have demonstrated exceptional effectiveness in treating a variety of cancers, including neuroendocrine tumors, breast cancer, and renal cell carcinoma. The need for mTOR inhibitors has increased due to the rising geriatric population, who are more prone to autoimmune disorders and cancer.

Another important application of mTOR inhibitors is immunosuppression and organ transplantation. By inhibiting the immune system, these medications assist in avoiding organ rejection and increase the success rates of transplant procedures. Additionally, continued research and development initiatives are broadening the potential application of mTOR inhibitors in other autoimmune conditions such as rheumatoid arthritis and lupus, suggesting new market opportunities.

Rising Prevalence of Cancer Contributes to the Market Share

The market for mTOR inhibitors is growing at a rapid pace due to the increasing prevalence of cancer. The World Health Organization (WHO) estimated that cancer is the second biggest cause of death worldwide, making it one of the highest priorities of healthcare governing bodies. The number of cancer cases is growing at a rapid pace each year. As the global population grows older, they are prone to develop cancer. mTOR inhibitors, like everolimus and temsirolimus, have proven to be remarkably effective in treating a variety of cancer types, including neuroendocrine tumors, breast cancer, and renal cell carcinoma.

mTOR inhibitors have shown promising results in restraining tumor progression. Their ability to specifically target cellular pathways makes them a good treatment option for cancer, particularly in cases where traditional therapies may be less effective. Indian Council of Medical Research (ICMR) stated that the country's average cancer case count for 2022 was 100.4 per 100,000 people, with a high proportion of women (estimated at 105.4 per 100,000) receiving a breast cancer diagnosis. Based on the data from Cancer Research UK, more than 27.5 million new cancer cases are expected globally by 2040.

Multiple Uses of mTOR Inhibitors

The versatility of mTOR inhibitors, with their expanding therapeutic applications, represents a significant trend driving the growth of the global mTOR inhibitors market. Initially recognized for their profound impact on cancer treatment, mTOR inhibitors are being actively researched for a broader spectrum of diseases. The broadening scope of potential applications is attracting increased interest and investment in the market, bolstering its potential. Recent scientific endeavors have shed light on the role of mTOR pathways in various autoimmune diseases, such as lupus and rheumatoid arthritis.

Preliminary results from clinical trials and studies indicate positive outcomes, with mTOR inhibitors showing positive results in reducing disease activity and improving patient's quality of life. Also, potential applications of mTOR inhibitors in neurodegenerative diseases, metabolic disorders, and certain rare diseases are being discovered through research. As scientists continue to explore treatment methodologies by mTOR inhibitors and their role in various diseases, the application of mTOR inhibitors will expand.

Moreover, the expansion in therapeutic applications translates to a more diversified market, attracting pharmaceutical companies to invest in research and development initiatives centered on mTOR inhibitors. In April 2022, Nobelpharma America became the first company to receive FDA approval for a topical treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC). The approval covers a topical gel formulation of sirolimus, an mTOR inhibitor also known as rapamycin.

Increasing Volume of Organ Transplantations

An important medical procedure that saves many lives every year is organ transplantation, which is a major factor propelling the growth of the global mTOR inhibitors market. The number of transplant patients has increased, and with it the increased demand for efficient immunosuppressive medications such as mTOR inhibitors.

mTOR inhibitors are essential for post-transplant treatment as they suppress the immune system and reduce the chance of organ rejection. Their value lies in their capacity to target immune cells that cause organ rejection while sparing others, to preserve the organs' long-term viability after transplantation. In addition, mTOR inhibitors have become well-known in the transplant community due to their comparative benign adverse effect profile when compared to certain immunosuppressant medications that came earlier. Therefore, mTOR inhibitors are more widely accepted and used in transplantation protocols, which is supporting the global mTOR inhibitor market. In 2021, 13,861 people nationwide donated their organs after their death, according to the US Department of Health and Human Services and the Health Resources and Services Administration. The number broke the record for deceased donations for the eleventh year in a row and was increased by 10.1% over the previous year, or 2020. In May 2021, the weekly total of deceased donors surpassed 300 for the first time, in June 2021, the 300-donor threshold was surpassed twice.

Rapamycin Dominates The Drug Type Segment

Rapamycin, also known as Sirolimus, differs from other calcineurin inhibitors like tacrolimus and cyclosporine because of the way it targets mTOR. The signaling system of the mammalian target of rapamycin (mTOR) is linked to the development of several illnesses, including cancer, neurological diseases, genetic disorders, and obesity, as it regulates cell growth and proliferation. Since sirolimus targets mTOR, which is involved in many essential biological processes, it has a wide range of therapeutic uses outside of organ transplantation. In addition to being utilized in organ transplantation, the medication can be used to coat coronary stents to prevent the body's system from rejecting newly donated organs and to treat lymphangioleiomyomatosis, a rare lung condition. The increasing popularity of Sirolimus coated balloons for treating peripheral vascular disease in western countries has come out as new advancement. Patients are benefiting from the treatment method and is being considered an effective approach.

North America Dominates mTOR Inhibitor Market

North America dominates the global mTOR inhibitor market, due to factors such as a high number of cancer patients, increasing geriatric population, innovations, and advancements in cancer therapeutics and treatment. Modern hospitals, academic institutions, and a highly qualified healthcare workforce defines North America's advanced and well-established healthcare infrastructure. The infrastructure facilitates the creation, testing, and generalized use of novel treatments such as using mTOR inhibitors.

Many pharmaceutical and biotechnology businesses are leading the way in mTOR inhibitor research and development. These companies consistently allocate resources toward state-of-the-art research, clinical trials, and drug discovery, hence aiding in the development of novel and enhanced mTOR inhibitors. For instance, kidneys, liver, heart, lungs, pancreas, and intestine are the most frequently transplanted organs in the United States, according to data from the Centers for Disease Control and Prevention (CDC) for 2021. Approximately 75,000 people are on the active waiting list for organ transplants daily.

Future Market Scenario (2024 - 2031F)

With the advent of new and improved mTOR inhibitors, such as dual mTORC1/mTORC2 inhibitors the market is expected to grow at a fast pace. New age mTOR inhibitors show better treatment outcomes and fewer side effects than previous generation inhibitors.

Personalized treatment strategies that use mTOR inhibitors to target genetic alterations and pathways are becoming more and more popular as precision medicine gains traction.

Global regulatory bodies are building frameworks to speed up the development of specialized oncology departments, which is driving the expansion of mTOR Inhibitor market worldwide.

Numerous studies have demonstrated the ability of rapamycin and other rapalogs to postpone the development of cancer. Rapamycin prevents cancer in several dozen murine models in a robust and reproducible manner. Rapamycin delays the onset of cancer in genetically predisposed individuals who have received cancer treatment by slowing down the growth of tumors and the proliferation of cells.

Key Players Landscape and Outlook

The market for mTOR inhibitors is competitive with several major companies investing in the development of novel and cutting-edge treatments. The key players are making significant R&D investments to bring new medications to market as the need for mTOR inhibitors arises.

In February 2022, Cambrian Biopharma entered a strategic collaboration with Novartis. Under the partnership, Novartis supplied innovative compounds specifically designed to target the mTOR pathway for research and development purposes.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global mTOR Inhibitors Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Type
  • 4.2.1. Rapamune
  • 4.2.2. Afinitor
  • 4.2.3. Torisel
  • 4.2.4. Zortress
  • 4.2.5. Omipalisib
  • 4.2.6. Others
• 4.3. By Application
  • 4.3.1. Cancer
  • 4.3.2. Immunosuppression
  • 4.3.3. Organ Transplantation
  • 4.3.4. Others
• 4.4. By End-user
  • 4.4.1. Hospital Pharmacies
  • 4.4.2. Retail Pharmacies
  • 4.4.3. Online Pharmacies
  • 4.4.4. Others
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia-Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East and Africa
• 4.6. By Company Market Share (%), 2023

5. Global mTOR Inhibitors Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Type
    • 5.1.2.1. Rapamune
    • 5.1.2.2. Afinitor
    • 5.1.2.3. Torisel
    • 5.1.2.4. Zortress
    • 5.1.2.5. Omipalisib
    • 5.1.2.6. Others
  • 5.1.3. By Application
    • 5.1.3.1. Cancer
    • 5.1.3.2. Immunosuppression
    • 5.1.3.3. Organ Transplantation
    • 5.1.3.4. Others
  • 5.1.4. By End-user
    • 5.1.4.1. Hospital Pharmacies
    • 5.1.4.2. Retail Pharmacies
    • 5.1.4.3. Online Pharmacies
    • 5.1.4.4. Others
  • 5.1.5. United States*
    • 5.1.5.1. Market Size & Forecast
    • 5.1.5.1.1. By Value
    • 5.1.5.1.2. By Volume
    • 5.1.5.2. By Type
    • 5.1.5.2.1. Rapamune
    • 5.1.5.2.2. Afinitor
    • 5.1.5.2.3. Torisel
    • 5.1.5.2.4. Zortress
    • 5.1.5.2.5. Omipalisib
    • 5.1.5.2.6. Others
    • 5.1.5.3. By Application
    • 5.1.5.3.1. Cancer
    • 5.1.5.3.2. Immunosuppression
    • 5.1.5.3.3. Organ Transplantation
    • 5.1.5.3.4. Others
    • 5.1.5.4. By End-user
    • 5.1.5.4.1. Hospital Pharmacies
    • 5.1.5.4.2. Retail Pharmacies
    • 5.1.5.4.3. Online Pharmacies
    • 5.1.5.4.4. Others
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Type
• 6.2. By Application
• 6.3. By End-user
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Demand Supply Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework & Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. AbbVie Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Astra Zeneca PLC
• 13.3. Bayer AG
• 13.4. Boehringer Ingelheim International Gmbh
• 13.5. Abott Inc.
• 13.6. Bristol-Myers Squibb Co
• 13.7. Pfizer Inc.
• 13.8. Merck & Co., Inc.
• 13.9. Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals Inc)
• 13.10. F. Hoffmann-La Roche Ltd
• 13.11. Novartis AG
• 13.12. Sanofi S A
• 13.13. Eisai Co. Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer